Hara Capital LLC Invests $2.58 Million in Novo Nordisk A/S $NVO

Hara Capital LLC bought a new stake in Novo Nordisk A/S (NYSE:NVO) during the third quarter, according to its most recent filing with the SEC. The firm bought 46,417 shares of the company’s stock, valued at approximately $2,576,000. Novo Nordisk A/S comprises 1.5% of Hara Capital LLC’s holdings, making the stock its 17th biggest holding.

Several other institutional investors have also recently bought and sold shares of the company. True Wealth Design LLC grew its position in shares of Novo Nordisk A/S by 209.8% in the third quarter. True Wealth Design LLC now owns 443 shares of the company’s stock valued at $25,000 after purchasing an additional 300 shares during the last quarter. NewSquare Capital LLC lifted its position in shares of Novo Nordisk A/S by 174.1% during the 2nd quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock worth $31,000 after purchasing an additional 282 shares during the last quarter. Mid American Wealth Advisory Group Inc. bought a new stake in Novo Nordisk A/S during the 2nd quarter valued at approximately $37,000. Maseco LLP bought a new stake in Novo Nordisk A/S during the 2nd quarter valued at approximately $39,000. Finally, Steigerwald Gordon & Koch Inc. acquired a new stake in Novo Nordisk A/S in the 3rd quarter valued at approximately $39,000. Institutional investors own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on NVO shares. Zacks Research upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Friday, January 9th. HSBC reaffirmed a “hold” rating and set a $54.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, December 10th. Morgan Stanley reiterated an “underweight” rating and issued a $42.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, December 3rd. Jefferies Financial Group started coverage on Novo Nordisk A/S in a research note on Monday, October 27th. They set an “underperform” rating on the stock. Finally, Hsbc Global Res cut Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a report on Monday, November 24th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, eleven have given a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of “Hold” and a consensus price target of $56.21.

Novo Nordisk A/S Price Performance

Shares of Novo Nordisk A/S stock opened at $62.28 on Friday. The firm has a market cap of $278.08 billion, a P/E ratio of 18.10 and a beta of 0.66. The firm’s 50-day simple moving average is $51.85 and its 200-day simple moving average is $54.85. Novo Nordisk A/S has a twelve month low of $43.08 and a twelve month high of $93.80. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.57 and a current ratio of 0.78.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.77 by $0.25. The firm had revenue of $11.79 billion during the quarter, compared to analyst estimates of $11.98 billion. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. As a group, research analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.